Not exactly — and the difference is the whole point. Here's what Mounjaro actually is, how it works, and who makes it.
Mounjaro is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It activates two different gut hormone receptors — GIP and GLP-1 — while drugs like Ozempic and Wegovy activate GLP-1 alone.
Per FDA prescribing information for tirzepatide (Mounjaro), Eli Lilly. Not medical advice.
GIP and GLP-1 are both incretin hormones your gut releases after eating. Tirzepatide activates both; semaglutide activates GLP-1 only.
The added GIP activity is believed to contribute to the larger average A1C and weight reductions seen in head-to-head trial data against GLP-1-only drugs.
Mounjaro is still commonly grouped under the broader "GLP-1 drugs" umbrella in casual use — it's just not accurate at the molecular level.
One email at launch · free trial · no credit card